Since 2000, Gavi, the Vaccine Alliance has driven unprecedented progress in immunisation. Through the leadership of developing countries, supported by the other Gavi partners, close to half a billion children have been immunised, which will lead to 6 million lives saved. Donors have acknowledged these achievements by endorsing Gavi as “very good value for money” and by committing nearly US$ 12 billion in funding to date.

Gavi is recognised as a leader in innovative and sustainable approaches to development, supporting countries to secure a healthy and prosperous future. Joint investments and engagement by the public and private sectors are yielding social and economic returns far beyond what any country or agency could achieve alone.

**THE OPPORTUNITY**

We have before us the opportunity to build upon and consolidate the gains achieved so far by investing together in the unfinished agenda of global immunisation.

As the world nears the 2015 deadline for the Millennium Development Goals, Gavi is continuing to scale up current interventions and is looking ahead to the next chapter – aspiring to a world free from vaccine-preventable diseases. However, one in five children worldwide are not fully protected even with the most basic vaccines, and only a minority have access to the full range of new, powerful vaccines against the most fatal diseases. Most of these underimmunised children live in Gavi-supported countries.

Country ownership and long-term sustainability are at the heart of the Gavi model. Gavi support is based on country demand, and all countries pay a share of the cost of their vaccines that are funded by Gavi. This helps to ensure that immunisation programmes are sustained after Gavi’s financial support ends.

From a 20-year perspective (see figure 2), the coming five years are likely to be the peak of investment for Gavi. Over the long term, needs are expected to decrease as 22 countries are graduating from Gavi support by 2020. In the following five-year periods, the required Gavi financing will continue to decrease, with a growing number of countries graduating from Gavi support and fully financing their own immunisation programmes.
INVESTING TOGETHER: AN ADDITIONAL US$ 7.5 BILLION NEEDED TO SAVE 5 TO 6 MILLION LIVES

Realising the goal of a healthy and sustainable future requires bold investments by all partners, with Gavi-supported countries at the forefront. With growing economies they will nearly triple their co-financing contributions in 2016–2020 compared with the previous five-year period, contributing US$ 1.2 billion to the cost of new vaccines.

Gavi’s work with vaccine manufacturers to supply high-quality vaccines at lower prices to developing countries will continue to break down barriers of access, even in the poorest countries and the most marginalised communities. From 2010 to 2013 the Vaccine Alliance secured a 37% reduction in the total vaccine cost to immunise a child with pentavalent, pneumococcal and rotavirus vaccines.

Gavi needs to secure additional resources of US$ 7.5 billion to respond to country demand and meet the total expenditure need of US$ 9.5 billion for 2016–2020. Gavi expects to have resources of US$ 2 billion already available for the next strategic period. The replenishment ask of US$ 7.5 billion (US$ 1.5 billion per year) assumes continued vaccine price reductions. If vaccine manufacturers respond to this challenge, and as country co-financing levels increase, Gavi donors’ share of financing could be reduced from approximately 80% in 2011–2015 to less than 60% in 2016–2020.

> Figure 3 PROJECTED IMPACT OF DYNAMIC RESOURCE MOBILISATION MODEL ON DONOR SHARE OF TOTAL FINANCING

TOWARDS A HEALTHY FUTURE

Now is the time to:

- accelerate impact by introducing life-saving vaccines in countries that have yet to do so, and by strengthening the systems needed to deliver routine immunisation.
- reach every child in Gavi-supported countries with life-saving vaccines, including those who have fallen through the cracks of inequity and are not fully protected even with the most basic vaccines, and expand access to new, improved vaccines.
- ensure the gains and investments of the past 15 years are consolidated and sustained so countries can increase their immunisation coverage and eventually take over full financing of their immunisation programmes. Consistent and catalytic support in this period will be fundamental to the success of the 22 countries expected to graduate from Gavi support by 2020.

*Compared to 2010 baseline price

WHY GAVI, THE VACCINE ALLIANCE

As a 21st century public-private development partnership, Gavi, the Vaccine Alliance applies market-based approaches to help solve public health challenges. Gavi draws on the strengths and complementarities of all the key stakeholders in global immunisation, including implementing and donor governments, the World Health Organization, UNICEF, the World Bank, the Bill & Melinda Gates Foundation, civil society, the vaccine industry, research and technology institutes and private companies, to redress global inequities in access to vaccines. By creating synergies, coordinating existing systems and avoiding duplication, the Vaccine Alliance is having an impact far beyond what could be achieved by any one country or organisation alone.

The Vaccine Alliance has a proven track record in delivery, efficiency and transparency, which has been commended in recent donor and multilateral evaluations. Gavi was also ranked second of 67 development agencies and donor governments in the 2013 Aid Transparency Index. Gavi’s efficient operating model ensures that US$ 0.97 of every dollar invested goes towards providing vaccines and delivering immunisation services to children in need.
The term lives saved is used throughout this document to denote the impact of the Vaccine Alliance investments in terms of future deaths averted through the prevention of death due to infectious diseases in childhood as well as death due to cancer in adulthood. Immunisation averts deaths over the lifetimes of vaccinated children by providing immunological protection from a young age. Some vaccines, for example human papillomavirus (HPV) vaccine, prevent deaths due to cancer decades in the future, through protection conferred at the time of immunisation.

2. Gavi-supported countries refers to the 72 countries currently supported by the Vaccine Alliance.
3. These are the five antigens included in the pentavalent vaccine (diphtheria, tetanus, pertussis, Haemophilus influenza type B and hepatitis B), Bacillus Calmette–Guérin, polo, measles, rubella, pneumococcus and rotavirus vaccine. The HPV vaccine is not listed here because it targets a different age group.

Gavi Partners

unicef
BILL & MELINDA GATES foundation
World Health Organization
THE WORLD BANK
Gavi
The Vaccine Alliance

Cover photo: Gavi/2014/Evelyn Hockstein (front), UNICEF/ NYHQ2009-0248/Estey (back)